Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vulvar carcinoma.

R L Coleman1, J T Santoso

  • 1University of Texas, Southwestern Medical Center, Division of Gynecologic Oncology, 5323 Harry Hines Blvd., J7.124, Dallas, TX 75235-9032, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).

Gynecologic oncology·2023
Same author

For ovarian cancer PARPi maintenance therapy: more is better, right?

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.

Gynecologic oncology·2021
Same author

Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

The forefront of ovarian cancer therapy: update on PARP inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Vulvar cancer, often linked to HPV, affects postmenopausal women. Treatment focuses on conservative surgery and radiation therapy to improve outcomes and quality of life.

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology

Background:

  • Vulvar carcinoma is a rare malignancy predominantly affecting postmenopausal women.
  • Human Papillomavirus (HPV) DNA is frequently associated with vulvar lesions, though the preinvasive-invasive link is not always clear.
  • Delayed diagnosis is common due to patient symptoms and physician evaluation challenges.

Purpose of the Study:

  • To review current management strategies for vulvar carcinoma.
  • To highlight advancements in surgical techniques and radiation therapy for vulvar cancer.
  • To evaluate the impact of conservative treatments on patient outcomes.

Main Methods:

  • Surgical staging following tumor resection.
  • Analysis of conservative surgical approaches, including separate incision resection of vulvar mass and groin.

Related Experiment Videos

  • Evaluation of radiation therapy and chemoradiation, including neoadjuvant and adjuvant applications.
  • Assessment of radiotherapy techniques as an alternative to groin dissection in select cases.

    • Main Results:

    • Conservative surgical procedures aim to preserve normal tissue, potentially improving wound healing and quality of life.
    • Neoadjuvant therapy can enable surgical resection of unresectable lesions.
    • Radiotherapy and chemoradiation contribute to organ preservation and improved local control.
    • Adjuvant therapy reduces the risk of groin recurrence.
    • Treatment of the pelvis alongside the groin improves survival in patients with positive lymph nodes.

    Conclusions:

    • Multimodality therapy, combining surgery, radiation, and chemotherapy, is crucial for extending survival in women with vulvar cancer.
    • Ongoing evaluation of conservative procedures is necessary to confirm their long-term survival benefits.
    • Tailored treatment strategies incorporating radiotherapy and conservative surgery offer promising outcomes for vulvar cancer patients.